Guidelines for the administration of biological therapy in patients with inflammatory bowel diseases: fourth, updated edition
2019
Abstract
Biological treatment (BL) of inflammatory bowel disease (IBD), Crohn's Disease (CN) and ulcerative colitis (UC), is currently a standard component of drug therapy for both diseases.. Its administration is associated with higher quality of life of patients, lower need for corticotherapy, lower number of relapses and related reduction of patients' incapacity for work [1-3].
BL reduces the need for surgical treatment of intestinal inflammation and its long-term consequences, thus reducing the risk of severe disability associated with adverse CD and UC progression.